{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:45:07Z","timestamp":1792755907630,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jinf.2024.106225","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T16:15:37Z","timestamp":1720455337000},"page":"106225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"89","author":[{"given":"Bing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0189-3739","authenticated-orcid":false,"given":"Hassen","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-8370","authenticated-orcid":false,"given":"Prabha","family":"Andraweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-7707","authenticated-orcid":false,"given":"Mark","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106225_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-genet-120213-092007","article-title":"The genetics of Neisseria species","volume":"48","author":"Rotman","year":"2014","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.jinf.2024.106225_bib2","unstructured":"WHO. Gonorrhoea (Neisseria gonorrhoeae infection); 2023. \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/gonorrhoea-(neisseria-gonorrhoeae-infection)#:%E2%88%BC:text=In%202020%2C%20WHO%20estimated%2082.4,people%20in%20high%20burden%20countries\u3009."},{"issue":"11","key":"10.1016\/j.jinf.2024.106225_bib3","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"issue":"7","key":"10.1016\/j.jinf.2024.106225_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/OLQ.0000000000001332","article-title":"Planning for a gonococcal vaccine: a narrative review of vaccine development and public health implications","volume":"48","author":"Abara","year":"2021","journal-title":"Sex Transm Dis"},{"issue":"4","key":"10.1016\/j.jinf.2024.106225_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/INF.0000000000003047","article-title":"VA-MENGOC-BC vaccination induces serum and mucosal anti Neisseria gonorrhoeae immune responses and reduces the incidence of gonorrhea","volume":"40","author":"Reyes Diaz","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.jinf.2024.106225_bib6","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3201\/eid2206.151093","article-title":"Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway","volume":"22","author":"Whelan","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"Supplement 1","key":"10.1016\/j.jinf.2024.106225_bib7","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1093\/ofid\/ofx180.002","article-title":"Possible impact of wide-scale vaccination against serogroup B neisseria meningitidis on gonorrhea incidence rates in one region of quebec, canada","volume":"4","author":"Longtin","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"10102","key":"10.1016\/j.jinf.2024.106225_bib8","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jinf.2024.106225_bib9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2024.106225_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","volume":"22","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2024.106225_bib11","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1097\/OLQ.0000000000001793","article-title":"Healthy vaccinee bias and MenB-FHbp vaccine effectiveness against gonorrhea","volume":"50","author":"Abara","year":"2023","journal-title":"Sex Transm Dis"},{"issue":"2","key":"10.1016\/j.jinf.2024.106225_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/vaccines8020219","article-title":"The Neisseria gonorrhoeae vaccine candidate NHBA elicits antibodies that are bactericidal, opsonophagocytic and that reduce gonococcal adherence to epithelial cells","volume":"8","author":"Semchenko","year":"2020","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.jinf.2024.106225_bib13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jinf.2024.106225_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008602","article-title":"The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae","volume":"16","author":"Leduc","year":"2020","journal-title":"PLoS Pathog"},{"issue":"4","key":"10.1016\/j.jinf.2024.106225_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/infdis\/jiab450","article-title":"Meningococcal detoxified outer membrane vesicle vaccines enhance gonococcal clearance in a murine infection model","volume":"225","author":"Matthias","year":"2022","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2024.106225_bib16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106225_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00031-8","article-title":"Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK","author":"Ladhani","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106225_bib18","article-title":"Vaccine value profile for Neisseria gonorrhoeae","author":"Lyu","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jinf.2024.106225_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00094-23","article-title":"Neisseria gonorrhoeae vaccines: a contemporary overview","volume":"37","author":"Williams","year":"2024","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.jinf.2024.106225_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ije\/22.4.742","article-title":"Estimation of vaccine effectiveness using the screening method","volume":"22","author":"FARRINGTON","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.jinf.2024.106225_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5596\/c14-016","article-title":"Product review: covidence (systematic review software)","volume":"35","author":"Babineau","year":"2014","journal-title":"J Can Health Libr Assoc"},{"key":"10.1016\/j.jinf.2024.106225_bib22","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2024.106225_bib23","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2024.106225_bib24","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jinf.2024.106225_bib25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/SMJ.0b013e31817a7ee4","article-title":"Odds ratios and risk ratios: what's the difference and why does it matter?","volume":"101","author":"Viera","year":"2008","journal-title":"South Med J"},{"issue":"2","key":"10.1016\/j.jinf.2024.106225_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.7774\/cevr.2019.8.2.110","article-title":"A meningococcal B vaccine induces cross-protection against gonorrhea","volume":"8","author":"Azze","year":"2019","journal-title":"Clin Exp Vaccin Res"},{"issue":"2","key":"10.1016\/j.jinf.2024.106225_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jinf.2023.05.021","article-title":"4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation","volume":"87","author":"Wang","year":"2023","journal-title":"J Infect"},{"issue":"8","key":"10.1016\/j.jinf.2024.106225_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.31742","article-title":"Association of group B meningococcal vaccine receipt with reduced gonorrhea incidence among university students","volume":"6","author":"Robison","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jinf.2024.106225_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00236-6","article-title":"Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2\u00d7 2 factorial design","author":"Molina","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2024.106225_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/vaccines7010005","article-title":"Effectiveness of a group b outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study","volume":"7","author":"Paynter","year":"2019","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.jinf.2024.106225_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/OLQ.0000000000001771","article-title":"Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: a case-control study","volume":"50","author":"Raccagni","year":"2023","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.jinf.2024.106225_bib32","doi-asserted-by":"crossref","first-page":"E1341","DOI":"10.1093\/cid\/ciac436","article-title":"Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California","volume":"76","author":"Bruxvoort","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2024.106225_bib33","unstructured":"Molina J-M, Ber\u00e7ot B, Assoumou L, Algarte-Genin M, Rubenstein E, Pialoux G, et al. ANRS 174 DOXYVAC: an open-label randomized trial to prevent STIs IN MSM ON PrEP. Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington; 2023."},{"key":"10.1016\/j.jinf.2024.106225_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.03.068","article-title":"Review of mathematical models of Neisseria gonorrhoeae vaccine impact: implications for vaccine development","author":"Padeniya","year":"2024","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.jinf.2024.106225_bib35","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","article-title":"Postexposure doxycycline to prevent bacterial sexually transmitted infections","volume":"388","author":"Luetkemeyer","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jinf.2024.106225_bib36","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2304007","article-title":"Doxycycline prophylaxis to prevent sexually transmitted infections in women","volume":"389","author":"Stewart","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jinf.2024.106225_bib37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","article-title":"Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial","volume":"18","author":"Molina","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"38","key":"10.1016\/j.jinf.2024.106225_bib38","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1016\/j.vaccine.2023.07.048","article-title":"The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting","volume":"41","author":"Padeniya","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jinf.2024.106225_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-022-14670-z","article-title":"The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study","volume":"23","author":"Looker","year":"2023","journal-title":"BMC Public Health"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:34:52Z","timestamp":1728009292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324001592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0163445324001592"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106225","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106225"}}